Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden

The aim of this study was to determine whether the burden of JAK2 (V617F) allele correlated with major clinical outcomes in patients with polycythemia vera ( PV). To this end, we determined JAK2 mutant allele levels in granulocytes of 173 PV patients at diagnosis. The mean ( +/- s. d.) mutant allele burden was 52% ( 729); 32 patients ( 18%) had greater than 75% mutant allele. The burden of JAK2 V617F allele correlated with measurements of stimulated erythropoiesis ( higher hematocrit, lower mean cell volume, serum ferritin and erythropoietin levels) and myelopoiesis ( higher white cell count, neutrophil count and serum lactate dehydrogenase) and with markers of neutrophil activation ( elevated leukocyte alkaline phosphatase and PRV- 1 expression). As compared to those with less than 25% mutant allele, patients harboring greater than 75% JAK2 V617F allele were at higher relative risk ( RR) of presenting larger spleen ( RR 4.7; Po0.001) or suffering from pruritus ( RR 3.1; Po0.001). In these patients, the risk of requiring chemotherapy ( RR 1.8; P 0.001) or developing major cardiovascular events ( RR 7.1; P 0.003) during follow up were significantly increased. We conclude that a burden of JAK2 (V617F) allele greater than 75% at diagnosis points to PV patients with high- risk disease.